SSA
NRXP icon

Schonfeld Strategic Advisors’s NRX Pharmaceuticals NRXP Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.3K Buy
+19,876
New +$40.1K ﹤0.01% 1991
2022
Q1 		– Sell
-2,810
Closed -$135K – 2809
2021
Q4 		$135K Buy
+2,810
New +$203K ﹤0.01% 1836

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BFG
Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Schonfeld Strategic Advisors's NRXP Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in NRX Pharmaceuticals (NRXP) in Q1 2026: 19,876 shares worth $42.3K. The stake represents ﹤0.01% of the portfolio and ranks #1991 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in NRXP as recently as Q4 2021.

Schonfeld Strategic Advisors first reported a position in NRXP in Q4 2021 and has held it in 2 quarters since. The position peaked at $135K in Q4 2021. 33 funds tracked by Wall St. Rank hold NRXP as of Q1 2026.

  • Schonfeld Strategic Advisors held 19,876 shares of NRX Pharmaceuticals worth $42.3K as of Q1 2026.
  • NRX Pharmaceuticals was a new Schonfeld Strategic Advisors position in Q1 2026.
  • NRX Pharmaceuticals made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1991 holding.
  • Schonfeld Strategic Advisors first reported a position in NRX Pharmaceuticals in Q4 2021 and has held it in 2 quarters since.
  • Schonfeld Strategic Advisors's NRX Pharmaceuticals position peaked at $135K in Q4 2021.
  • 33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.